Table 2 Clinical trials with anti-CD 19 or anti-CD22 ITs in patients with relapsed lymphoma
| Â | Â | Â | Â | Â | Â | Â | Clinical Response | Â | Â | |
|---|---|---|---|---|---|---|---|---|---|---|
Toxin | Antibodya | Infusion | No. of Patients Evaluable | Dose-Limiting Toxicity | IT Half-Life (hr) | MTD | CRb | PRC | Anti-Mouse IgG/Anti-Toxin Antibody Response (%) | Reference |
dgRTA | RFB4 (Fab’) | b.i. | 14 | VLS,d rhabdomyolysis | 1.5 | 75 mg/m2 | 0 | 5 | 36 | (37) |
| Â | RFB4 (IgG) | b.i. | 24 | VLS, rhabdomyolysis | 7.8 | 20 mg/m2 | 1 | 5 | 62.5 | (38) |
| Â | RFB4 (IgG) | c.i. | 16 | VLS | 10.7 | 20 mg/m2 | 4 | 0 | 75 | (39) |
| Â | HD37 | b.i. | 23 | VLS, rhabdomyolysis | 18.2 | 16 mg/m2 | 1 | 1 | 25 | (40) |
| Â | Â | c.i. | 9 | VLS, acrocyanosis | 22.8 | 19 mg/m2 | 0 | 1 | 30 | (40) |
| Â | HD37 | b.i. | 7 | VLS, hypotension | 17.0 | 8 mg/m2 | 0 | 0 | 33 | (41) |
bRT | B4 | b.i. | 25 | Liver dysfunction, thrombocytopenia | NRe | 50 µg/Kg/d × 5 | 1 | 2 | 48 | (42) |
|  | B4 | b.i. | 34 | As above plus myalgias | NR | 50 µg/Kg/d × 7 | 2 | 3 | 53 | (42) |
|  | B4 | c.i. | 12f | Thrombocytopenia, arthralgias | NR | 40 µg/Kg/d (2 cycles every 28 days) | 8g | 0 | 58 | (42) |
|  | B4 | c.i. | 49f | Anorexia, myalgias | NR | 30 µg/Kg/d (2 cycles every 14 days) | 30g | 0 | 49 | (42) |
PAP | B43 | b.i. | 30 | VLS | 14.0 | 100 µg/Kg/day × 5 | NR | NR | NR | (43) |